424 related articles for article (PubMed ID: 21119733)
21. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors.
Ross DM; Arthur C; Burbury K; Ko BS; Mills AK; Shortt J; Kostner K
Intern Med J; 2018 Feb; 48 Suppl 2():5-13. PubMed ID: 29388307
[TBL] [Abstract][Full Text] [Related]
22. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
23. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
24. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics.
Giansanti P; Preisinger C; Huber KV; Gridling M; Superti-Furga G; Bennett KL; Heck AJ
ACS Chem Biol; 2014 Jul; 9(7):1490-8. PubMed ID: 24804581
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.
Josephs DH; Fisher DS; Spicer J; Flanagan RJ
Ther Drug Monit; 2013 Oct; 35(5):562-87. PubMed ID: 24052062
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
Dasanu CA; Padmanabhan P; Clark BA; Do C
Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
[TBL] [Abstract][Full Text] [Related]
28. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitors protect the salivary gland from radiation damage by increasing DNA double-strand break repair.
Affandi T; Ohm AM; Gaillard D; Haas A; Reyland ME
J Biol Chem; 2021; 296():100401. PubMed ID: 33571522
[TBL] [Abstract][Full Text] [Related]
30. Small molecule tyrosine kinase inhibitors in glioblastoma.
Kim G; Ko YT
Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429
[TBL] [Abstract][Full Text] [Related]
31. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Kimura S; Ashihara E; Maekawa T
Curr Pharm Biotechnol; 2006 Oct; 7(5):371-9. PubMed ID: 17076652
[TBL] [Abstract][Full Text] [Related]
32. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
33. Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
Leukemia; 2009 Dec; 23(12):2304-8. PubMed ID: 19675589
[No Abstract] [Full Text] [Related]
34. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors in pediatric malignancies.
Skolnik JM; Adamson PC
Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
Haake SM; Li J; Bai Y; Kinose F; Fang B; Welsh EA; Zent R; Dhillon J; Pow-Sang JM; Chen YA; Koomen JM; Rathmell WK; Fishman M; Haura EB
Clin Cancer Res; 2016 Nov; 22(22):5605-5616. PubMed ID: 27220961
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
Bixby D; Talpaz M
Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
[TBL] [Abstract][Full Text] [Related]
38. Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions.
Hu C; Dong X
Curr Med Chem; 2019; 26(31):5811-5824. PubMed ID: 30009703
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
[TBL] [Abstract][Full Text] [Related]
40. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Tinsley SM
J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
